title: [Combined antiretroviral therapy for prevention of vertical HIV-1 transmission].
abstract: A 25-year old woman with rapid HIV disease progression had been receiving zidovudine (ZDV) for two years, when she became pregnant. She had a high viral load and carried out zidovudine-resistant viral strains. For these reasons, and with the main objective to maximally reduce viremia, the association of DDI to ZDV was introduced a few weeks before delivery. The virological follow-up for one year has confirmed the lack of HIV infection in the child. Combined antiretroviral therapy during the last weeks of pregnancy might be considered for the prevention of vertical transmission of HIV in cases of high risk of newborn infection, without adding relevant toxicity.
authors.affiliation: Servicio de Medicina Interna, Hospital Príncipe de Asturias, Alcalá de Henares, Madrid.
authors.forename: E
authors.initials: E
authors.lastname: Casas
authors.forename: M
authors.initials: M
authors.lastname: Gómez-Cano
authors.forename: M
authors.initials: M
authors.lastname: Adrados
authors.forename: G
authors.initials: G
authors.lastname: García-Lerma
authors.forename: F
authors.initials: F
authors.lastname: Calvo
authors.forename: V
authors.initials: V
authors.lastname: Soriano
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D016049:Didanosine / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000635:transmission; D015497:HIV-1; D006801:Humans; D018445:Infectious Disease Transmission, Vertical / Q000517:prevention & control*; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy*; D015215:Zidovudine / Q000627:therapeutic use*
chemical_list: D019380:Anti-HIV Agents; D015215:Zidovudine; D016049:Didanosine